BCR and neoplasm: The T and B cell receptor (TCR and BCR) repertoire, the neo-antigenic immune targets [10–13] and, more recently, finer definitions of the frequency of immune cell subsets in tumors have revealed important molecular heterogeneities that are not intrinsic to the melanoma cells, but extend to the associated tumor components that shape the tumor microenvironment [14].